• Immunovia’s extraordinary general meeting on October 29, 2026, approved a rights issue potentially raising approximately SEK 63.4 million before costs.
• Each SEK 0.06 unit comprises two shares and one warrant series TO 4, issued free of charge.
• Subscription runs November 9–23, 2026; TO 4 exercise runs April 19–May 3, 2027, at SEK 0.03 per share.
• Shareholders adopted amendments to the Articles of Association changing the limits for share capital and the number of shares.
• The meeting authorized share and warrant issuance to guarantors as compensation, on rights issue terms, until the next annual general meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovia AB published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.